Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · brain-umap@2

SRR2170408

GTEX

7ad77503-083c-500a-b90c-b5ed7a0984c7

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
GTEX
cancer_type_detailed
—
subtype
—
cancer_type
GTEX
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • OXIDATIVE_PHOSPHORYLATION+0.432
  • PROTEIN_SECRETION+0.431
  • MTORC1_SIGNALING+0.387
  • ANDROGEN_RESPONSE+0.348
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.343
  • CHOLESTEROL_HOMEOSTASIS+0.337
  • HEME_METABOLISM+0.323
  • TNFA_SIGNALING_VIA_NFKB+0.275
  • MYC_TARGETS_V1+0.270
  • INFLAMMATORY_RESPONSE+0.264

Top 10 suppressed

  • WNT_BETA_CATENIN_SIGNALING-0.376
  • NOTCH_SIGNALING-0.276
  • HEDGEHOG_SIGNALING-0.236
  • MYC_TARGETS_V2-0.210
  • G2M_CHECKPOINT-0.200
  • DNA_REPAIR-0.180
  • E2F_TARGETS-0.180
  • APICAL_SURFACE-0.100
  • KRAS_SIGNALING_DN-0.100
  • P53_PATHWAY-0.064

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1SRR1092797
brain-umap@2
GTEX—0.829
2SRR1321853
brain-umap@2
GTEX—0.807
3BS_HV8PFRBR
brain-umap@2
pilocytic astrocytoma—0.795
4e5ae4a47-9a0d-4a70-a7be-40bddeb3d017
colon-landscapes@1
——0.791
5MDT-AP-0173
medullo-epn-umap@date-based
MedMedulloblastoma0.785
6SJEPD031285_D1.RNA-Seq
medullo-epn-umap@date-based
EPNEPN Tumor0.781
7SRR4195686
colon-landscapes@1
——0.780
8BS_T0RKFEKR
brain-umap@2
pilocytic astrocytoma—0.772
9SRR660661
brain-umap@2
GTEX—0.760
10BS_M026T44Q
brain-umap@2
Meningioma—0.759

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 37 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
OXIDATIVE_PHOSPHORYLATION0.432Remibrutinib— uncovered
PROTEIN_SECRETION0.431Remibrutinib— uncovered
MTORC1_SIGNALING0.387Inavolisib— uncovered
ANDROGEN_RESPONSE0.348Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.343Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.337Remibrutinib— uncovered
HEME_METABOLISM0.323Temsirolimus— uncovered
TNFA_SIGNALING_VIA_NFKB0.275Inavolisib— uncovered
MYC_TARGETS_V10.270Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.264Idelalisib— uncovered
PEROXISOME0.258Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.254Idelalisib— uncovered
APOPTOSIS0.253Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.248Inavolisib— uncovered
SPERMATOGENESIS0.232Inavolisib— uncovered
FATTY_ACID_METABOLISM0.229Inavolisib— uncovered
ADIPOGENESIS0.224Inavolisib— uncovered
KRAS_SIGNALING_UP0.207Inavolisib— uncovered
ANGIOGENESIS0.201Remibrutinib— uncovered
IL2_STAT5_SIGNALING0.201Idelalisib— uncovered